Archived Investigations
Hims & Hers Health, Inc. (NYSE: HIMS)
Hims & Hers and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On June 23, 2025, Novo Nordisk announced that it was terminating its partnership with Hims, disclosing that the Company had “failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of ‘personalization’ and are disseminating deceptive marketing that put patient safety at risk,” and that “the ‘semaglutide’ active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies” may contain “unsafe and illicit foreign ingredients.”
On this news, the price of Hims’ shares fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025, on unusually heavy trading volume.
The first-filed case is Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315. A subsequent case, Yaghsizian v. Hims & Hers Health, Inc., No. 25-cv-05321, expanded the class period.